Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.
Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...
We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...
Sarepta dominates the Duchenne muscular dystrophy market. Find out why recent insider buying of SRPT stock may signal ...
These two could become direct competitors relatively soon.
In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other best mid cap growth stocks. 50 Basis Point Reduction: Exaggeration or Hidden Benefit ...
Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...
Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the ...
Night - Clear. Winds N. The overnight low will be 53 °F (11.7 °C). Sunny with a high of 85 °F (29.4 °C). Winds from N to NNE at 4 to 7 mph (6.4 to 11.3 kph). Sunny today with a high of 88 °F ...